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ORAL PRESENTATIONS
Conclusion: Ammonia is an independent predictor of ACLF and its
associated mortality in clinically stable outpatients with cirrhosis. An
ammonia level over 1.48 times the ULN defines the high-risk group
for ACLF.
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Background and aims: Onset of decompensation in cirrhosis is
associated with poor outcome. The current clinico-biochemical tools
have limited accuracy in predicting outcomes reliably. Identifying the
predictors with precision model on the big data using artificial
intelligence may improve predictability. We aimed to develop a
machine learning (ML) based prognostic model for predicting 90 day
survival in patients of cirrhosis presenting with decompensation.
Method: We analysed electronic medical records retrospectively of
hospitalised cirrhosis patients at the ILBS, with a complete 90-day
follow-up. Clinical data, laboratory parameters and organ involvement were serially noted. AI-modelling was done after appropriate
mining, feature engineering, splitted randomly into train and testsets (20:80). The class imbalance problem was handled by random
over-sampling technique, to make balanced 50:50 ratios. After 10fold cross validation, 3 repetitions and grid search for optimal hyper
parameters, the XGB-CV model was chosen. AUC was the primary
selection criteria and confusion matrix was used to compare AUCs
between AI-models and existing indices; CTP and MELD-score.
Results: Total of 6326 patients [mean age 48.2 ± 11.5 years, 84% male,
Mean CTP 10.4 ± 2.2 and MELD Na-30.4 ± 11.9, alcohol 49.4%] were
included. Ninety day mortality was 29.2%. Acute insult was identified
in 80% cases; of which extra-hepatic 49%, hepatic 46% and unknown
5% cases respectively. The XGB-CV model had the best accuracy for
prediction of 90 days event in the train set 0.90 (0.90–0.93),
validation set 0.80 (0.79–0.81) and for overall dataset 0.80 (0.79–
0.81). The AUC of the XGB-CV model was better than CTP and MELD
Na-score by 16% and 15% respectively. The prediction model
considered 43 variables; 18 of which predicted the outcome, and 10
maximum contributors are shown in concordance classifier. The
most contributors to poor outcome included, index presentation as
HE, diagnosis of AD/ACLF/ESLD, PT-INR, serum creatinine, total
bilirubin, acute insult etiology, prior decompensation, acute hepatic
or extrahepatic insult, leukocyte count and present duration of
illness. In the Decision Tree Model, the presence of HE, PT-INR and
syndromic diagnosis of AD or ACLF/ESLD was able to stratify the
patients into low (22%), intermediate (23–46%) and high risk (>75%)
of mortality at 90 days.
Conclusion: The AI based current model developed using a large data
base of CLD patients presenting with decompensation immensely
adds to the current indices of liver disease severity and can stratify
patients at admission. Simple ML algorithms using HE and INR
besides syndromic presentation, could help treatment decisions and
prognostication.
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Differential changes in global and antigen-specific B cell
frequencies and function associate with the outcome of HBV
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Background and aims: Despite HBsAg loss and the development of
anti-HBs being the hallmark of natural resolution of HBV or
achievement of ‘functional cure’, humoral immunity has not yet
been examined in the setting of nucleos (t)ide analog (NA)
discontinuation. We analysed HBcAg and HBsAg-specific frequencies
and functional potential longitudinally in HBeAg-negative chronic
Hepatitis B (CHB) patients stopping NA therapy to assess whether
HBsAg loss ± off-treatment viral control associated with a recovery of
the defective B cell response characteristic of CHB.
Method: Twenty-one HBeAg- CHB patients with complete viral
suppression (>3 years) and without cirrhosis were studied prospectively. 16-colour flow cytometry was used to quantitate and
phenotype circulating HBsAg- and HBcAg-specific B cells (dual
fluorochrome-labelled antigen baits), global B cells, plasmablasts
and Tfh at baseline, 12 and 48 weeks after stopping NA (W12 and
W48). Cultured ELISPOTs were used to longitudinally evaluate
antibody-secreting cells against HBsAg and HBcAg.
Results: After a median follow-up of 34 months (IQR 26–37), 16 (76%)
patients remained off-therapy, with 5 (24% of the total cohort) losing
HBsAg, whilst 5 (24%) required NA reintroduction. Frequencies of
HBsAg and HBcAg-specific B cells were comparable between groups at
baseline and did not correlate with levels of qHBsAg or HBcrAg
respectively, but did show differential temporal dynamics according
to clinical outcome. HBcAg-specific B cells increased at W12 in all
groups in association with viral rebound, but decreased to baseline
values by W48 only among those achieving HBsAg loss or being retreated. By contrast, patients remaining off-therapy had a significant
increase in HBsAg-specific B cells by W48 compared to re-treated
patients. Compared to patients remaining HBsAg+ after NA discontinuation, B cells in patients with HBsAg loss were enriched for the
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